



Supporting Information

for

Design, synthesis and biological evaluation of 2,5-diaryloxazolo[4,5-d]pyrimidin-7-ylamines as selective cytotoxic agents against HeLa cells

Maryna V. Kachaeva, Agnieszka B. Olejniczak, Marta Denel-Bobrowska,
Victor V. Zhirnov, Yevheniia S. Velihina, Stepan G. Pilyo and Volodymyr S. Brovarets

Beilstein J. Org. Chem. **2026**, 22, 390–398. [doi:10.3762/bjoc.22.27](https://doi.org/10.3762/bjoc.22.27)

Characterization data and copies of spectra

Table of contents

Analytical and spectral data of compounds 1–9	S2–S4
IR, ^1H , ^{13}C NMR and LC–MS spectra of products	S5
Figures S1–S36. IR, ^1H , ^{13}C NMR and LC–MS spectra of compounds 1–9 .	S5–S51

Analytical and spectral data of compounds 1–9

2,5-Diphenyl-*N*-(2-piperidin-1-ylpropyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (1)

Yield 80%. White solid, mp 161–163 °C. IR (KBr, cm⁻¹) ν_{\max} : 3336-2936 (NH, Ar-CH), 1647, 1553, 1483, 1381, 1367, 771, 702. ¹H NMR (400 MHz, CDCl₃) δ 8.54 (d, 2H, $J_{\text{HH}} = 8.0$ Hz, ArH), 8.31 (d, 2H, $J_{\text{HH}} = 8.0$ Hz, ArH), 7.60-7.56 (m, 3H, ArH), 7.47-7.45 (m, 3H, ArH), 6.35 (br s, 1H, NH), 4.08-3.88 (m, 1H, CH), 3.44 (br s, 1H, CH), 3.00 (br s, 1H, CH), 2.69 (br s, 2H, CH₂), 2.46 (br s, 2H, CH₂), 1.80-1.66 (m, 4H, 2CH₂), 1.53 (br s, 2H, CH₂), 1.13 (d, 3H, $J_{\text{HH}} = 8.0$ Hz, CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 165.0, 161.3, 148.2, 138.3, 132.3, 130.7, 129.9, 129.0, 128.4, 128.2, 128.1, 128.0, 126.6, 58.5, 49.1, 26.6, 26.5, 24.8, 11.1. LC-MS: m/z (%) 414.2 (96.7) [M+1]⁺. Anal. Calcd for C₂₅H₂₇N₅O: C, 72.61; H, 6.58; N, 16.94. Found: C, 72.53; H, 6.52; N, 16.76.

***N*-(2-Morpholin-4-ylpropyl)-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (2)**

Yield 80%. White solid, mp 186-188 °C. IR (KBr, cm⁻¹) ν_{\max} : 3307-2971 (NH, Ar-CH), 2807, 1645, 1581, 1512, 1480, 1449, 1368, 1311, 1265, 1217, 1144, 1114, 1024, 966, 923, 872, 773, 703. ¹H NMR (400 MHz, CDCl₃) δ 8.50-8.49 (m, 2H, ArH), 8.23-8.22 (m, 2H, ArH), 7.55-7.43 (m, 6H, ArH), 6.05 (br s, 1H, NH), 4.02-3.78 (m, 5H, ArH), 3.44 (t, 1H, $J_{\text{HH}} = 8$ Hz, CH), 2.95 (br s, 1H, CH), 2.70 (br s, 2H, CH₂), 2.54 (br s, 2H, CH₂), 1.13 (d, 3H, $J_{\text{HH}} = 8.0$ Hz, CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 165.0, 161.1, 148.0, 138.2, 132.5, 132.4, 130.0, 129.9, 129.0, 128.3, 128.2, 128.0, 126.4, 67.4, 58.3, 48.4, 42.8, 11.5. LC-MS: m/z (%) 416.2 (93.2) [M+1]⁺. Anal. Calcd for C₂₄H₂₅N₅O₂: C, 69.38; H, 6.06; N, 16.86. Found: C, 69.30; H, 6.00; N, 16.99.

***N*-[2-(4-Ethylpiperazin-1-yl)propyl]-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (3)**

Yield 76%. White solid, mp 145–147 °C. IR (KBr, cm⁻¹) ν_{\max} : 3381-2966 (NH, Ar-CH), 2811, 1642, 1502, 1369, 702. ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, 2H, $J_{\text{HH}} = 4$ Hz, ArH), 8.29 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.59-7.53 (m, 3H, ArH), 7.46-7.45 (m, 3H, ArH), 6.12 (br s, 1H, NH), 3.93-3.87 (m, 1H, CH), 3.51-3.45 (m, 1H, CH), 3.04-3.01 (m, 1H, CH), 2.79 (br s, 2H, CH₂), 2.61 (br s, 5H, 2CH₂, CH), 2.52-2.47 (m, 3H, CH₂, CH), 1.16-1.12 (m, 6H, 2CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 165.1, 161.3, 148.2, 138.2, 132.4, 129.9, 129.1, 129.0, 128.4, 128.2, 128.1, 128.0, 126.6, 57.9, 53.3, 52.4, 11.9, 11.6. LC-MS: m/z (%) 443.2 (100) [M+1]⁺. Anal. Calcd for C₂₈H₂₃N₅O₂: C, 72.87; H, 5.02; N, 15.17. Found: C, 72.76; H, 5.09; N, 15.41.

***N*-[2-(4-Chlorophenyl)-2-piperidin-1-ylethyl]-5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (4)**

Yield 79%. White solid, mp 198–200 °C. IR (KBr, cm⁻¹) ν_{\max} : 3326-2928 (NH, Ar-CH), 1680, 1636, 1552, 1481, 1366, 1159, 1093, 777, 690. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (d, 2H,

$J_{\text{HH}} = 8$ Hz, ArH), 8.26 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.61-7.52 (m, 3H, ArH), 7.37 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.27-7.25 (m, 4H, ArH), 5.95 (br s, 1H, NH), 4.13-4.01 (m, 2H, CH₂), 3.84-3.80 (m, 1H, CH), 2.57-2.53 (m, 2H, CH₂), 2.41-2.40 (m, 5H, CH₃, CH₂), 1.69-1.61 (m, 4H, 2CH₂), 1.44 (dd, 2H, $J_{\text{HH}} = 12, 8$ Hz, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 164.7, 161.3, 145.6, 140.1, 135.4, 135.3, 133.6, 132.4, 130.0, 129.0, 128.9, 128.5, 128.3, 128.0, 126.5, 125.3, 36.9, 26.5, 23.8, 21.5, 17.5. LC-MS: m/z (%) 525.2 (95.8) [M+1]⁺. Anal. Calcd for C₃₁H₃₀ClN₅O: C, 71.05; H, 5.77; Cl, 6.76; N, 13.36. Found: C, 71.13; H, 5.80; Cl, 6.87; N, 13.56.

***N*-[2-(4-Chlorophenyl)-2-morpholin-4-ylethyl]-5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (5)**

Yield 76%. White solid, mp 225–227 °C. IR (KBr, cm⁻¹) ν_{max} : 3301-2821 (NH, Ar-CH), 1641, 1552, 1480, 1368, 1110. ¹H NMR (500 MHz, CDCl₃) δ 8.36 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 8.21 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.57 (t, 1H, $J_{\text{HH}} = 8$ Hz, ArH), 7.52 (t, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.37 (d, 2H, $J_{\text{HH}} = 4$ Hz, ArH), 7.28-7.23 (m, 4H, ArH), 5.60 (1H, NH), 4.24-4.19 (m, 1H, CH), 4.09-3.77 (m, 6H, CH, 2CH₂), 2.57-2.54 (m, 4H, 2CH₂), 2.40 (s, 3H, CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 165.2, 161.3, 147.8, 140.2, 135.3, 132.4, 130.0, 129.0, 128.8, 128.3, 128.1, 126.4, 68.2, 67.2, 50.5, 37.1, 21.4. LC-MS: m/z (%) 526.2 (95.6) [M+1]⁺. Anal. Calcd for C₃₀H₂₈ClN₅O₂: C, 68.50; H, 5.37; Cl, 6.74; N, 13.31. Found: C, 68.45; H, 5.31; Cl, 6.89; N, 13.44.

11-(2,5-Diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl)-7,11-diazatricyclo[7.3.1.0_{2,7}]trideca-2,4-dien-6-one (6)

Yield 75%. White solid, mp 225–227 °C. IR (KBr, cm⁻¹) ν_{max} : 3057, 2847, 1654, 1613, 1603 (C=O), 1545, 1475, 1373, 1067, 771, 698. ¹H NMR (400 MHz, CDCl₃) δ 8.42-8.40 (m, 2H, ArH), 8.21 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.61-7.52 (m, 3H, ArH), 7.44-7.43 (m, 3H, ArH), 7.14 (t, $J_{\text{HH}} = 8$ Hz, 1H, ArH), 6.27 (t, $J_{\text{HH}} = 8$ Hz, 1H, ArH), 6.16 (t, $J_{\text{HH}} = 8$ Hz, 1H, ArH), 5.03 (dd, $J_{\text{HH}} = 28, 12$ Hz, 2H, CH₂), 4.21 (d, 1H, $J_{\text{HH}} = 16$ Hz, CH), 3.97 (dd, $J_{\text{HH}} = 16, 8$ Hz, 1H, CH), 3.46 (d, 2H, $J_{\text{HH}} = 12$ Hz, CH₂), 3.27 (br s, 1H, CH), 2.73 (br s, 1H, CH), 2.17 (br s, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 164.9, 163.3, 162.5, 160.4, 148.6, 148.2, 138.6, 137.8, 132.6, 130.0, 129.1, 128.3, 128.2, 128.2, 128.0, 127.8, 126.1, 117.6, 105.3, 49.1, 34.9, 27.8, 26.4. LC-MS: m/z (%) 462.2 (97.2) [M+1]⁺. Anal. Calcd for C₂₆H₃₀N₆O: C, 70.50; H, 6.75; N, 18.76. Found: C, 70.56; H, 6.83; N, 18.99.

11-[5-(4-Methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0_{2,7}]trideca-2,4-dien-6-one (7)

Yield 71%. White solid, mp 263–265 °C. IR (KBr, cm⁻¹) ν_{max} : 3057, 2946, 1817, 1652, 1601 (C=O), 1572, 1547, 1449, 1371, 1144, 810, 777, 712, 689. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 8.19 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.59-7.50 (m, 3H, ArH), 7.23 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 7.13 (t, 1H, $J_{\text{HH}} = 8$ Hz, ArH), 6.26 (d, 2H, $J_{\text{HH}} = 8$ Hz, ArH), 6.15 (d, 2H,

$J_{\text{HH}} = 8$ Hz, ArH), 5.00 (q, 2H, $J_{\text{HH}} = 12$ Hz, CH₂), 4.19 (d, 2H, $J_{\text{HH}} = 16$ Hz, CH), 3.96 (dd, 1H, $J_{\text{HH}} = 16, 8$ Hz, CH), 3.43 (d, 2H, $J_{\text{HH}} = 8$ Hz, CH₂), 3.26 (br s, 1H, CH), 2.72 (br s, 1H, CH), 2.40 (s, 3H, CH₃), 2.15 (br s, 1H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 164.8, 163.3, 162.4, 148.7, 148.1, 140.1, 138.6, 135.2, 132.5, 129.0, 128.9, 128.3, 127.9, 127.7, 126.1, 117.6, 105.3, 51.5, 49.1, 34.8, 27.8, 26.3, 21.5. LC-MS: m/z (%) 476.2 (100) [M+1]⁺. Anal. Calcd for C₂₉H₂₅N₅O₂: C, 73.25; H, 5.30; N, 14.73. Found: C, 73.31; H, 5.38; N, 14.89.

11-[2,5-Bis(4-methylphenyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0_{2,7}]trideca-2,4-dien-6-one (8)

Yield 70%. White solid, mp > 250 °C. IR (KBr, cm⁻¹) ν_{max} : 2921, 2242, 1610 (C=O), 1552, 1494, 1470, 1414, 1319, 1277, 1125, 1088, 1010, 822, 736. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (d, 2H, $J_{\text{HH}} = 10$ Hz, ArH), 8.07 (d, 2H, $J_{\text{HH}} = 10$ Hz, ArH), 7.41 (d, 2H, $J_{\text{HH}} = 10$ Hz, ArH), 7.31 (d, 2H, $J_{\text{HH}} = 10$ Hz, ArH), 7.13 (t, 1H, $J_{\text{HH}} = 10$ Hz, ArH), 6.27 (d, 1H, $J_{\text{HH}} = 10$ Hz, ArH), 6.16 (d, 1H, $J_{\text{HH}} = 5$ Hz, ArH), 5.02 (dd, $J_{\text{HH}} = 35, 10$ Hz, 2H, CH₂), 4.21 (d, $J_{\text{HH}} = 15$ Hz, 1H, CH), 3.97 (dd, $J_{\text{HH}} = 15, 10$ Hz, 1H, CH), 3.44 (d, $J_{\text{HH}} = 10$ Hz, 2H, CH₂), 3.27 (s, 1H, CH), 2.73 (s, 1H, CH), 2.47 (s, 3H, CH₃), 2.44 (s, 3H, CH₃), 2.16 (s, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 165.2, 163.2, 148.7, 143.4, 138.6, 131.1, 130.0, 130.0, 129.8, 129.0, 128.6, 128.6, 128.3, 128.1, 127.9, 127.6, 123.2, 117.5, 49.1, 38.0, 34.8, 27.8, 26.3, 21.9. LC-MS: m/z (%) 490.2 (95.9) [M+1]⁺. Anal. Calcd for C₃₀H₂₇N₅O₂: C, 73.60; H, 5.56; N, 14.30. Found: C, 73.67; H, 5.65; N, 14.57.

6-[(2,5-Diphenyl[1,3]oxazolo[4,5-*d*]pyrimidin-amino-7-yl)]-*N*-methyl-(2R,3R,4S,5S)-hexane-1,2,3,4,5-pentaol (9)

Yield 65%. White solid, mp 210–212 °C. IR (KBr, cm⁻¹) ν_{max} : 3396 (OH), 1631, 1550, 1389, 1110, 1092, 1071, 1022, 769, 703. ¹H NMR (500 MHz, CF₃C(O)OD) δ 7.58–7.50 (m, 4H, ArH), 7.13–7.04 (m, 2H, ArH), 7.00–6.96 (m, 4H, ArH), 4.35–4.00 (m, 3H, CH₂, CH), 3.85–3.80 (m, 1H, CH), 3.76–3.72 (m, 1H, CH), 3.64–3.37 (m, 3H, CH₂, CH), 3.26, 3.05 (s, 3H, CH₃). ¹³C NMR (126 MHz, CF₃C(O)OD) δ 169.3, 154.2, 1495, 135.0, 134.0, 128.9, 128.7, 127.8, 127.7, 127.1, 126.8, 126.8, 121.3, 71.5, 70.8, 68.6, 66.8, 53.5, 52.5, 37.8. LC-MS: m/z (I_{rel} , %): 467.2 [M+H]⁺ (100). Found, %: C 61.65; H 5.60; N 12.45. C₂₄H₂₆N₄O₆. Calculated, %: C 61.79; H 5.62; N 12.01.




Figure S1. IR spectrum of 2,5-diphenyl-*N*-(2-piperidin-1-ylpropyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**1**)




Figure S2. ¹H NMR spectrum of 2,5-diphenyl-*N*-(2-piperidin-1-ylpropyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**1**)




Figure S3. ¹³C NMR spectrum of 2,5-diphenyl-*N*-(2-piperidin-1-ylpropyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**1**)




Figure S4. LC-MS spectrum of 2,5-diphenyl-*N*-(2-piperidin-1-ylpropyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**1**)




Figure S5. IR spectrum of *N*-(2-morpholin-4-ylpropyl)-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**2**)




Figure S6. ¹H NMR spectrum of *N*-(2-morpholin-4-ylpropyl)-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (2)





Figure S7. ^{13}C NMR spectrum of *N*-(2-morpholin-4-ylpropyl)-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (2)



CLQ394866

L969949D

LCMS-27


SUPOR_30.M

19:33 26.08.2025

Product not found

No product

#	RT	DAD1A	DAD1B	MSD1	MSD2	ELSD	MSD1 ions	MSD1 rt	MSD2 ions	MSD2 rt	Info
1	1.140	93.2%	90.5%	83.5%	100.0%	100.0%	416.2(98),208.6(2)	1.145	414.2(50),450.2(50)	1.146	
2	1.194	---	1.8%	1.7%	---	---	430.2(100)	1.200	---	---	
3	1.588	6.8%	7.7%	14.9%	---	---	359.2(100)	1.594	---	---	



MSD1-Sub TIC | 1000 | 2000
 MS D1 180 194 175 170
 DAD1B 215 215 215 215 215 215 215 215 215 215
 DAD1A 215 215 215 215 215 215 215 215 215 215
 http://www.chemspider.com/Chemical-Block.aspx?CID=15912309&CID=CLQ394866




Figure S8. LC–MS spectrum of *N*-(2-morpholin-4-ylpropyl)-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**2**)




Figure S9. IR spectrum of *N*-[2-(4-ethylpiperazin-1-yl)propyl]-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**3**)




Figure S10. ^1H NMR spectrum of *N*-[2-(4-ethylpiperazin-1-yl)propyl]-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**3**)






Figure S11. ^{13}C NMR spectrum of *N*-[2-(4-ethylpiperazin-1-yl)propyl]-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (3)



CLQ394867

L969949D
 LCMS-27
 SUPOR_30.M
 19:36 26.08.2025
 Product not found
 No product

#	RT	DAD1A	DAD1B	MSD1	MSD2	ELSD	MSD1 ions	MSD1 rt	MSD2 ions	MSD2 rt	Info
1	1.200	---	---	---	17.7%	---	---	---	477.2(100)	1.206	
2	1.202	100.0%	100.0%	100.0%	71.8%	100.0%	443.2(66),222.2(34)	1.207	441.2(87),479.0(13)	1.206	
3	1.210	---	---	---	10.5%	---	---	---	442.2(56),478.0(44)	1.216	



MSD1-Sub 7271+1000-1000
 MSD1-Sub 7271+1000-1000
 DATE: 2025-08-26 19:36:00
 FILE: L969949D SUPOR_30.M
 http://portal.easylab.com/CLQ394867/MSD1-Sub 7271+1000-1000




Figure S12. LC–MS spectrum of *N*-[2-(4-ethylpiperazin-1-yl)propyl]-2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**3**)




Figure S13. IR spectrum of *N*-[2-(4-chlorophenyl)-2-piperidin-1-ylethyl]-5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**4**)




Figure S14. ¹H NMR spectrum of *N*-[2-(4-chlorophenyl)-2-piperidin-1-ylethyl]-5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**4**)





Figure S15. ^{13}C NMR spectrum of *N*-[2-(4-chlorophenyl)-2-piperidin-1-ylethyl]-5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**4**)



CLQ394868

L969947

LCMS-27





SUPOR_30.M


19:32 26.08.2025

Product not found

No product

#	RT	DAD1A	DAD1B	MSD1	MSD2	ELSD	MSD1 ions	MSD1 rt	MSD2 ions	MSD2 rt	Info
1	1.511	95.8%	93.2%	92.1%	41.9%	100.0%	525.2(88),528.2(7),263.6(5)	1.518	560.2(52),562.2(48)	1.518	
2	1.514	---	---	---	58.1%	---	---	---	524.2(100)	1.520	
3	1.652	4.4%	5.4%	7.2%	---	---	373.2(100)	1.656	---	---	
4	1.792	---	1.1%	0.7%	---	---	322.0(100)	1.798	---	---	








Figure S16. LC-MS spectrum of *N*-[2-(4-chlorophenyl)-2-piperidin-1-ylethyl]-5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**4**)




Figure S17. IR spectrum of *N*-[2-(4-chlorophenyl)-2-morpholin-4-ylethyl]-5-(4-methylphenyl)-2-phenyl[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**5**)




Figure S18. ^1H NMR spectrum of *N*-[2-(4-chlorophenyl)-2-morpholin-4-ylethyl]-5-(4-methylphenyl)-2-phenyl[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**5**)





Figure S19. ^{13}C NMR spectrum of *N*-[2-(4-chlorophenyl)-2-morpholin-4-ylethyl]-5-(4-methylphenyl)-2-phenyl[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**5**)



CLQ394869

L969949D

LCMS-27





SUPOR_30.M


19:39 26.08.2025

Product not found

No product

#	RT	DAD1A	DAD1B	MSD1	MSD2	ELSD	MSD1 ions	MSD1 rt	MSD2 ions	MSD2 rt	Info
1	1.512	95.6%	93.4%	92.1%	41.9%	100.0%	526.2(88),529.2(7),263.6(5)	1.518	560.2(52),562.2(48)	1.518	
2	1.514	---	---	---	58.1%	---	---	---	524.2(100)	1.520	
3	1.652	4.4%	5.4%	7.2%	---	---	373.2(100)	1.656	---	---	
4	1.792	---	1.1%	0.7%	---	---	322.0(100)	1.798	---	---	








Figure S20. LC-MS spectrum of *N*-[2-(4-chlorophenyl)-2-morpholin-4-ylethyl]-5-(4-methylphenyl)-2-phenyl[1,3]oxazolo[4,5-*d*]pyrimidin-7-amine (**5**)




Figure S21. IR spectrum of 11-(2,5-diphenyl-[1,3]oxazolo[4,5-d]pyrimidin-7-yl)-7,11-diazatricyclo[7.3.1.0(2,7)]trideca-2,4-dien-6-one (**6**).




Figure S22. ¹H NMR spectrum of 11-(2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl)-7,11-diazatricyclo[7.3.1.0^{2,7}]trideca-2,4-dien-6-one (**6**)




Figure S23. ¹³C NMR spectrum of 11-(2,5-diphenyl-[1,3]oxazolo[4,5-d]pyrimidin-7-yl)-7,11-diazatricyclo[7.3.1.0(2,7)]trideca-2,4-dien-6-one (**6**)




Figure S24. LC-MS spectrum of 11-(2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl)-7,11-diazatricyclo[7.3.1.0_{2,7}]trideca-2,4-dien-6-one (**6**)




Figure S25. IR spectrum of 11-[5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0(2,7)]trideca-2,4-dien-6-one (**7**)




Figure S26. ¹H NMR spectrum of 11-[5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-d]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0^{2,7}]trideca-2,4-dien-6-one (7)






Figure S27. ¹³C NMR spectrum of 11-[5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0(2,7)]trideca-2,4-dien-6-one (**7**)



CLQ394876

L970615D
 LCMS-37
 SUPOR_30.M
 16:50 27.08.2025
 Product not found
 No product

#	RT	DAD1A	DAD1B	MSD1	MSD2	ELSD	MSD1 ions	MSD1 rt	MSD2 ions	MSD2 rt	Info
1	1.496	100.0%	100.0%	100.0%	27.6%	100.0%	476.2(100)	1.506	510.2(100)	1.504	
2	1.893	---	---	---	72.4%	---	---	---	489.2(58),461.2(10),536.0(8)	1.901	






Figure S28. LC-MS spectrum of 11-[5-(4-methylphenyl)-2-phenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0_{2,7}]trideca-2,4-dien-6-one (**7**)




Figure S29. IR spectrum of 11-[2,5-bis(4-methylphenyl)-[1,3]oxazolo[4,5-d]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0(2,7)]trideca-2,4-dien-6-one (**8**)




Figure S30. ¹H NMR spectrum of 11-[2,5-bis(4-methylphenyl)-[1,3]oxazolo[4,5-d]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0^{2,7}]trideca-2,4-dien-6-one (**8**)




Figure S31. ¹³C NMR spectrum of 11-[2,5-bis(4-methylphenyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0(2,7)]trideca-2,4-dien-6-one (**8**)




Figure S32. LC-MS spectrum of 11-[2,5-bis(4-methylphenyl)-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl]-7,11-diazatricyclo[7.3.1.0_{2,7}]trideca-2,4-dien-6-one (**8**)




Figure S33. IR spectrum of 6-[(2,5-diphenyl-[1,3]oxazolo[4,5-d]pyrimidin-7-yl)-methylamino]hexane-1,2,3,4,5-pentol (**9**)




Figure S34. ^1H NMR spectrum of 6-[(2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl)-methylamino]hexane-1,2,3,4,5-pentol (**9**)






Figure S35. ¹³C NMR spectrum of 6-[(2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl)-methylamino]hexane-1,2,3,4,5-pentol (**9**)



CLQ394879

L970615D
 LCMS-37
 SUPOR_30.M
 17:02 27.08.2025
 Product not found
 No product

#	RT	DAD1A	DAD1B	MSD1	MSD2	ELSD	MSD1 ions	MSD1 rt	MSD2 ions	MSD2 rt	Info
1	1.154	100.0%	100.0%	100.0%	100.0%	100.0%	467.2(100)	1.165	465.2(40),501.2(36),579.2(12)	1.163	






Figure S36. LC–MS spectrum of 6-[(2,5-diphenyl-[1,3]oxazolo[4,5-*d*]pyrimidin-7-yl)-methylamino]hexane-1,2,3,4,5-pentol (**9**)